Genito-urinary Cancer

News alerts, weekly reports and conference planners

No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1	apalutamide Sensitive: A1 - Approval apalutamide Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	histrelin acetate Sensitive: A1 - Approval histrelin acetate Sensitive : A1	histrelin acetate Sensitive: A1 - Approval histrelin acetate Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1	cabazitaxel Sensitive: A1 - Approval cabazitaxel Sensitive : A1
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	enzalutamide Sensitive: A1 - Approval enzalutamide Sensitive : A1	enzalutamide Sensitive: A1 - Approval enzalutamide Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1	bevacizumab-bvzr Sensitive: A1 - Approval bevacizumab-bvzr Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1	relugolix Sensitive: A1 - Approval relugolix Sensitive : A1
No biomarker	Germ Cell Tumors	No biomarker	Germ Cell Tumors	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	etoposide IV Sensitive: A1 - Approval etoposide IV Sensitive : A1	etoposide IV Sensitive: A1 - Approval etoposide IV Sensitive : A1
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Testicular Cancer	No biomarker	Testicular Cancer	ifosfamide Sensitive: A1 - Approval ifosfamide Sensitive : A1	ifosfamide Sensitive: A1 - Approval ifosfamide Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	tivozanib Sensitive: A1 - Approval tivozanib Sensitive : A1	tivozanib Sensitive: A1 - Approval tivozanib Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	mitomycin urothelial gel Sensitive: A1 - Approval mitomycin urothelial gel Sensitive : A1	mitomycin urothelial gel Sensitive: A1 - Approval mitomycin urothelial gel Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1	temsirolimus Sensitive: A1 - Approval temsirolimus Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1	everolimus + lenvatinib Sensitive: A1 - Approval everolimus + lenvatinib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	docetaxel + prednisone Sensitive: A1 - Approval docetaxel + prednisone Sensitive : A1	docetaxel + prednisone Sensitive: A1 - Approval docetaxel + prednisone Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	abiraterone acetate Sensitive: A1 - Approval abiraterone acetate Sensitive : A1	abiraterone acetate Sensitive: A1 - Approval abiraterone acetate Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1	everolimus Sensitive: A1 - Approval everolimus Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1	degarelix Sensitive: A1 - Approval degarelix Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval bevacizumab + pegylated interferon α -2a Sensitive : A1	bevacizumab + pegylated interferon α -2a Sensitive: A1 - Approval bevacizumab + pegylated interferon α -2a Sensitive : A1
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1	olaparib Sensitive: A1 - Approval olaparib Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	darolutamide Sensitive: A1 - Approval darolutamide Sensitive : A1	darolutamide Sensitive: A1 - Approval darolutamide Sensitive : A1

Genito-urinary Cancer

Associations(1412)

Associations
(1412)